Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Minoxidil (oral & topical) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Dutasteride and Minoxidil (oral & topical) have evidence — compare verdict strength side-by-side.
Approved BPH dose is 0.5 mg once daily; off-label hair-loss use mirrors the same 0.5 mg once-daily dose under a clinician. A prescription drug.
anytime
Oral soft-gel capsule (dutasteride 0.5 mg)
Topical 2–5% solution or 5% foam applied to the scalp (men: 5% twice daily or once-daily foam; women: 2% twice daily or 5% foam once daily). Low-dose ORAL minoxidil is off-label and clinician-titrated, typically 0.25–5 mg once daily. A drug — not an approved supplement regimen.
anytime
Topical 5% foam/solution (OTC) for most; low-dose oral minoxidil under a clinician for poor topical responders
3–6 months
Months
Years
Weeks; may persist
3–6 months
3–6 months
Weeks to months
Throughout use
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Journal of the American Academy of Dermatology (2006) · Rct · n=416
Randomized placebo-controlled trial of 416 men comparing dutasteride doses, finasteride 5 mg, and placebo over 24 weeks
Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.
Journal of the American Academy of Dermatology (2010) · Rct · n=153
Phase-III randomized double-blind placebo-controlled trial of 153 men over 6 months
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
European urology (2010) · Rct · n=4844
CombAT: 4-year multicenter randomized double-blind trial in 4844 men with symptomatic BPH and prostatic enlargement
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Journal of the American Academy of Dermatology (2002) · Rct · n=393
48-week double-blind, placebo-controlled, multicenter RCT in 393 men with androgenetic alopecia
A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
Journal of the American Academy of Dermatology (2007) · Rct · n=352
16-week double-blind, placebo-controlled RCT of 5% minoxidil foam in 352 men (52-week open-label safety extension)
Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study.
Journal of drugs in dermatology : JDD (2016) · Rct · n=322
Phase III randomized, investigator-blinded trial in 322 women with female pattern hair loss
Minoxidil (oral & topical) has a higher evidence score (5.5/10 vs 5.4/10) and wins in 2 of 3 categories.
No known interactions between Dutasteride and Minoxidil (oral & topical) have been documented in our database. However, always consult a healthcare provider before combining supplements.